Key Takeaways
- Doctor-to-doctor sales usually deliver full cash at close and a short work-back. DSO deals mix cash, equity rollover, and multi-year employment commitments.
- Practices generating $1.5–3M in revenue often qualify for both buyer pools, so a side-by-side valuation can clarify the real outcomes.
- DSO transactions in 2026 commonly require a 5-year post-close employment term and shift compensation to an associate-level salary.
- McLerran’s structured auction process routinely lifts valuations by about 30% and creates leverage to negotiate stronger earnout and equity terms.
- Get a side-by-side valuation from McLerran & Associates to see what your practice is worth in both markets.
Comparing Doctor-to-Doctor Sales and DSO Affiliations
A doctor-to-doctor sale transfers ownership to an individual dentist buyer. The purchase price is typically paid in full at closing, the seller works back for only a few weeks, and the practice’s legacy passes directly to another clinician.
A DSO affiliation (Dental Service Organization) brings a corporate or private-equity-backed buyer to the table. Headline valuations can be higher, yet the deal usually includes a mix of cash, retained equity, and a multi-year employment commitment.
Owners generating roughly $1.5–3M in annual revenue sit in a genuine Venn diagram, qualified for both markets. Many in this range benefit from a true side-by-side valuation before choosing a path. Talk to McLerran’s valuation team to find out what your practice is worth in both markets.
Quick Comparison: Valuation, Structure, Autonomy, and Close Rate
| Dimension | Doctor-to-Doctor | DSO / PE Affiliation | McLerran & Associates Advantage |
|---|---|---|---|
| Valuation method | Percentage of annual collections or SDE multiple | Adjusted EBITDA multiple; ranges vary by practice size and specialty | CPA-led EBITDA analysis delivered for both paths before any decision |
| Cash at close | Typically 80–100% of purchase price at closing | Commonly 60–85% cash, with the remainder in equity rollover, earnout, and escrow | Multi-year cash-flow modeling shows real after-tax proceeds across structures |
| Work-back period | Typically 30–90 days | Minimum 5-year post-close employment now standard in 2026 deals | Employment-agreement terms negotiated, with non-punitive earnout provisions pursued |
| Autonomy post-close | New owner assumes all clinical and operational control | Clinical autonomy legally preserved via PC/MSO structure, while operational control transfers to the DSO | Buyer-vetting protocol screens for DSOs with strong post-close autonomy track records |
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is the profitability metric institutional buyers use to price practices. SDE (Seller’s Discretionary Earnings) is a similar measure used for smaller, owner-operated practices. Both figures are calculated after replacing the owner-doctor’s compensation with a market-rate associate salary.
Five-Year Work Commitments in DSO Sales
Most DSOs now require a minimum 5-year post-close employment term in 2026 deals, and provider continuity can be one of the main reasons buyers terminate processes. That commitment can mean 5 more years of clinical income plus potential equity upside, yet it also represents a major life decision.
Many owners find that this timeline deserves careful financial modeling before signing. Post-sale compensation in DSO deals usually shifts from owner-level distributions to an associate salary of roughly 25–30% of collections.
McLerran & Associates models this income change across 3-, 5-, 7-, and 10-year horizons, including conservative recapitalization assumptions. That work helps owners compare what each path may net over time, not just at closing.
Common DSO Deal Structures and Key Risks
Most DSO transactions include several components rather than all cash. The standard structure includes cash at close, rollover equity into the DSO’s holding company, a 1–3 year earnout, and an indemnification escrow held for 12–24 months.
- Joint-venture (JV) equity is tied to the individual practice or regional group. It typically pays distributions and can carry a higher floor but a lower ceiling.
- Holding-company equity is a stake in the DSO’s parent entity. It usually does not pay distributions, yet the potential upside at a future platform sale can be substantially larger.
Earnout structures carry meaningful risk because post-closing operational decisions, such as staffing, scheduling, and marketing, are controlled by the DSO and directly affect whether performance targets are met. That loss of control is why McLerran negotiates for non-punitive earnout provisions, such as pro-rata payouts for near-misses, and pushes for later start dates to account for integration periods.
McLerran’s structured auction process typically runs 45–60 days and generates around 10 offers. This competition can lift valuations by approximately 30% compared with going it alone and can create leverage to negotiate better terms on every component of the deal.
Protecting Your Legacy, Patients, and Team
In a doctor-to-doctor walk-away sale, the seller exits after a short transition, and the buying dentist assumes full stewardship of patients and staff. In a partnership or vest-out structure, the seller retains a stake and transitions gradually, which can fit larger practices that support two or more doctors.
In a DSO transaction, the organization usually retains existing staff for operational continuity, although employment terms and compensation structures are reworked under the DSO framework. Sellers can negotiate explicit staff-retention commitments in the purchase agreement and often benefit from doing so.
McLerran’s mandate is to balance price and fit. The firm’s buyer-vetting protocol screens out DSOs known for poor post-close environments, so the practices it represents are not shown to buyers with questionable track records with staff and patients.
Vetting DSOs and Identifying Strong Platforms
ADSO membership has grown significantly over the past several years, with the fastest growth in smaller regional platforms. Not all of these organizations are well-capitalized or well-run. As of mid-2025, approximately 130 private-equity-backed DSOs operated across the U.S. dental landscape, creating a crowded field where quality can vary sharply.
Vetting a DSO often means underwriting it like an investment. Key questions include whether the whole company is profitable, whether revenue is still growing at the practices it already owns, whether the management team is experienced, and whether the private equity firm behind it has completed this kind of recapitalization successfully before. These questions matter especially now because 78% of surveyed DSOs anticipate recapitalization within 12–36 months, which means the strength of the platform behind any equity rollover can directly affect whether that second liquidity event ever materializes.
McLerran maintains a pre-qualified buyer pool and has blacklisted DSOs known for creating poor post-close environments. The firm’s roughly 85–90% transaction rate, compared with an industry norm closer to 35–40%, reflects in part that buyers bid more aggressively on its listings because they know the deals are properly underwritten and the sellers are serious.
Learn how McLerran vets DSO buyers and what that process can mean for your outcome.
Revenue-Based Decision Matrix: Which Path Fits Your Practice?
Once you understand how to evaluate buyer quality, the next step is to see which buyer pool your practice fits. Revenue tier can be one of the main factors that shapes that decision.
| Annual Revenue Tier | Likely Best Path | Rationale |
|---|---|---|
| Under $1.5M | Doctor-to-doctor | The private-buyer pool is deepest at this tier, and DSO interest is limited for smaller, owner-dependent practices. Full cash at close and a short work-back are realistic. |
| $1.5M–$3M | Either path, side-by-side valuation recommended | Owners in this range often qualify for both markets. The same practice can produce valuations that differ by 40–80% depending on buyer type. McLerran’s roughly 50/50 split between paths supports a genuine comparison. |
| Over $3M | DSO / PE affiliation | The private-buyer pool able to finance acquisitions of $1M+ EBITDA practices is thin. Institutional buyers tend to dominate at this scale and may offer meaningfully higher multiples. |
Specialty can shift these thresholds. Oral and maxillofacial surgery and orthodontics, for example, have traded at a persistent premium to equivalent-sized general practices on adjusted EBITDA, which attracts institutional interest at lower revenue levels than general dentistry.
2026 Market Conditions and the Role of Competition
Dental practice multiples have moderated from the 13x–16x peak of 2021–2023 but remain attractive as of mid-2026. Ranges can depend on payer mix, provider depth, and systems. About 69% of DSOs expect their private equity sponsors to drive a moderate or high increase in acquisition activity in 2026, which can sustain demand for premier, Class A practices.
Offer dispersion is a key 2026 dynamic. The gap between best and middle-tier offers on the same practice sits near historic levels. Sellers running competitive processes averaged more than 5 offers and final values about 50% above initial offers. That gap shows why creating competition, rather than negotiating with a single buyer, can be one of the main drivers of outcome.
McLerran does not promise a specific multiple. The firm does commit to a diligence-grade valuation that controls the narrative around your EBITDA and a structured process that brings multiple vetted buyers to the table at the same time.
Pre-Transition Checklist: Documents Every Owner Should Gather
Gathering core documents early can speed up valuation and strengthen your position in diligence, regardless of which path you choose.
- Three years of profit-and-loss statements and tax returns
- Year-to-date production and collection reports by provider
- Payer mix breakdown (fee-for-service vs. insurance vs. Medicaid)
- Active patient count and new-patient trends (trailing 12–24 months)
- Associate and hygienist agreements, including compensation structures
- Real estate details, such as lease terms, renewal options, or ownership documentation
- Equipment list with approximate ages and any recent capital expenditures
- Any existing letters of intent, unsolicited offers, or prior valuations received
McLerran can remotely access practice management software and cross-reference these materials to build a CPA-led EBITDA analysis. This diligence-grade work is done up front so the numbers are more likely to hold when buyers scrutinize them and deals are less likely to be re-traded at the finish line.
Ready to Compare Both Paths with Full Information?
The decision between a doctor-to-doctor sale and a DSO affiliation rarely follows a one-size-fits-all pattern. It often depends on your practice’s size, profitability, specialty, and, most importantly, your personal goals for what comes next.
McLerran & Associates is one of the few sell-side advisory firms in the country that runs both paths in roughly equal measure. That experience can give owners a genuine side-by-side comparison that single-lane brokers may not provide.
With approximately 2,000 successful practice sales, roughly $2 billion in closed transaction volume, and more than 10,000 practices evaluated, McLerran brings the depth to suggest which path may fit your practice and what it might be worth in both markets.
Owners who are not yet sure whether selling is right for them can consider attending the McLerran M&A Summit (October 29–30, 2026), a dental-only event built for owners who have not decided yet. The event features expert panels, one-on-one CPA sessions, and a complimentary practice valuation (a $2,500 value).
When you are ready to understand your options with fuller information, connect with McLerran & Associates. Call (512) 900-7989, email info@dentaltransitions.com, or request a consultation online.
Frequently Asked Questions
What is the real difference between a doctor-to-doctor sale and a DSO affiliation for a practice generating $2M in revenue?
At the $2M revenue level, both paths are usually available, and the financial outcomes can differ substantially. In a doctor-to-doctor sale, the purchase price is typically calculated as a percentage of collections or a multiple of the seller’s discretionary earnings, paid largely in cash at closing, with the seller transitioning out in a matter of weeks.
In a DSO affiliation, the practice is valued on adjusted EBITDA, a profitability metric calculated after replacing the owner-doctor’s compensation with a market-rate associate salary. The headline number is often higher, yet it usually includes a mix of cash at close, retained equity in the DSO platform, and an earnout tied to future performance targets. The seller also commits to a multi-year employment agreement, typically 5 years in 2026 deals.
Neither path fits every situation. The better fit can depend on how much you value immediate liquidity versus potential upside, how many more years you want to practice clinically, and what you want for your staff and patients after the transition. McLerran & Associates produces a side-by-side valuation that quantifies your practice’s worth in both markets so you can compare with real numbers rather than estimates.
How does McLerran & Associates calculate a practice valuation, and why does it matter that a CPA leads the process?
McLerran builds every valuation from the ground up using a CPA-led EBITDA analysis. The process starts by accessing the practice’s management software and financial records, then unpacking discretionary, personal, and non-recurring expenses such as owner compensation above market rate, family members on payroll, personal insurance, continuing education, association dues, and one-time equipment purchases. This work helps arrive at true normalized profitability.
For doctor-to-doctor deals, value is expressed as a percentage of revenue or a multiple of net cash flow. For DSO deals, it is expressed as a multiple of adjusted EBITDA. CPA-led methodology can matter because of durability. When a DSO’s quality-of-earnings team scrutinizes the numbers during due diligence, a weak or back-of-the-napkin valuation can be challenged, and deals can be re-traded downward.
McLerran’s diligence-grade work is designed to hold up under that scrutiny, which is one reason the firm’s agreed values tend to survive to closing more often instead of eroding in the final stretch.
What should I look for and watch out for in a DSO earnout structure?
An earnout is a portion of the purchase price paid after closing, contingent on the practice meeting agreed performance targets, typically revenue or EBITDA benchmarks, over a defined period. As noted in the deal structure section, the fundamental earnout risk stems from the seller’s loss of operational control once the DSO assumes management.
After closing, the seller no longer controls the decisions that most directly affect those targets, such as staffing levels, scheduling, marketing spend, fee schedules, and insurance participation. A missed target through no fault of the seller can reduce or eliminate the deferred payment.
When negotiating earnout terms, some of the most important protections to pursue include pro-rata provisions, so a near-miss still pays most of the earnout rather than nothing, a later start date to account for integration disruption, and clearly defined “for cause” triggers that limit the DSO’s ability to restructure the practice in ways that make targets unachievable. McLerran negotiates these provisions on behalf of every client and models each earnout scenario in its multi-year cash-flow forecasts so owners can see a realistic range of outcomes, not just the best case.
How do I evaluate whether a DSO’s retained equity is actually worth anything?
Retained equity, sometimes called rollover equity, is the portion of a DSO deal paid not in cash but as an ownership stake in the DSO platform or its parent entity. It is illiquid until the platform is sold or recapitalized, which can take 5–10 years and may not produce a meaningful return if the DSO underperforms.
Evaluating this equity usually means treating the DSO like any other investment. Helpful questions include whether the company as a whole is profitable, not just the practices it recently acquired, whether revenue is still growing at locations it has owned for several years, whether the management team has a track record of successful exits, and whether the private equity firm behind it is experienced in healthcare services and has completed recapitalizations at favorable multiples before.
Because as much as 40% of a DSO deal can be structured as equity rather than cash, the quality of that equity can be a core part of the transaction economics rather than a secondary detail. McLerran vets buyers on these dimensions and steers clients away from undercapitalized or poorly run platforms before they reach the negotiating table.
Is now a good time to sell, or should I wait for the market to improve?
Valuations for premier dental practices remain near all-time highs as of mid-2026, with strong institutional demand and a high-demand, low-supply environment for Class A assets. As discussed earlier, valuations remain near historical highs despite moderating from the 2021–2023 peak.
The more useful question is often not whether the market is at its absolute peak, but whether your practice is positioned to command a strong outcome right now and whether you have the right representation to capture it. McLerran can provide a candid assessment of where your practice stands. If the timing does not appear right, the firm can update your valuation at no charge a year later rather than encourage a transaction that does not fit your goals.
